YourWay Cannabis

LATEST MEDICINAL CANNABIS STOCK NEWS


Aleafia Health Announces Closing of $5.6M Private Placement

Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce that it has closed its previously announced private placement (the “Private Placement”) representing aggregate gross proceeds of approximately $5.6 million. Pursuant to the Private Placement, an aggregate of 68,151,515 units were issued at a price of $0.0825 per unit, with each unit consisting of one... Read more


SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment SciSparc Ltd. (NASDAQ: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has received approval from the Ethics Committee of The Soroka... Read more


Item 9 LabsNears Completion of Cannabis Cultivation and Lab Facility in Pahrump, Nevada

20,000 Square-Foot, State-of-the-Art Facility Anticipated To Be Fully Operational by End of 2022 Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—is pleased to announce today that its new 20,000 square-foot, state-of-the-art cultivation and lab facility in Pahrump, N.V. (the "Nevada Facility")... Read more


Tilray Medical Welcomes Government of Luxembourg Delegation Visit to European Campus in Portugal

Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, welcomes the Luxembourg Ministry of Health Delegation to the Company’s European campus and facility located in Cantanhede, Portugal. Tilray’s EU-GMP-certified medical cannabis... Read more


Body and Mind Reports Q3 FY2022 Financial Results

Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) (the "Company" or "BaM"), a multi-state US cannabis operator, is pleased to report its financial results for the third fiscal quarter ended April 30, 2022. Q3 FY2022 Financial Summary (results expressed in USD$ unless otherwise indicated): Reported Q3 FY2022 revenue of $7.88 million, a 10% increase over Q3 FY2021 revenue of $7.16 million; Q3 FY2022 Gross profit of... Read more


Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo’s platform for organism design and development, Cronos has... Read more


Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments  Safety data reinforce excellent tolerability profile of Zygel  Company will focus resources on FXS and 22q development  Cash runway extended through the end of 2023 / early 2024  Zynerba to host conference call and webcast tomorrow, June 22, 2022 at... Read more


Innocan Pharma Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new PCT patent application entitled "Compositions for Treatment of Vaginal Atrophy" on June 12, 2022, claiming priority from a US provisional patent. Vaginal atrophy is a condition associated with loss of moisture, thinning, and inflammation of the vaginal walls, which can be... Read more


Tilray: Broken Coast Cannabis Launches Full Spectrum ‘woah’

Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced the expansion of Broken Coast’s best-selling premium cannabis portfolio with the launch of their summer lineup of products, including; premium craft-cannabis BC (British... Read more


Trulieve Cannabis Opening New Port Richey, FL Medical Marijuana Dispensary

New dispensary expands patient access to medical cannabis; grand opening specials available Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the opening of a new medical dispensary in New Port Richey, Fla. Located at 5422 US Hwy 19, the doors will open at 9 a.m. on Thursday, June 16,... Read more


HEXO Reports Third Quarter 2022 Results

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 2, 2022 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021. All $ figures in Canadian thousands unless otherwise stated HEXO Corp (TSX: HEXO; NASDAQ: HEXO) ("HEXO" or the “Company"), a leading producer of high-quality cannabis... Read more


Medical Marijuana Subsidiary Kannaway® Achieves Largest Revenue Month in Company History for Japan Division in May 2022

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that in May its subsidiary Kannaway® has achieved its largest revenue month in the company’s history for its Japan division. According to one of the most recent... Read more


Innocan Pharma Reports Successful Preliminary Trial Results Regarding Epilepsy in Dogs

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the successful preliminary results of a small-scale efficacy trial in dogs with refractory (drug-resistant) epilepsy. In this initial phase, the dogs were treated with Innocan Pharma's LPT (CBD Loaded Liposome Platform) injection. The results demonstrate that these dogs had a decrease in the... Read more


Khiron Life Sciences Announces Closing Of $4.6 Million Overnight Brokered Offering Including Full Exercise Of Over-allotment Option

Khiron Life Sciences Corp. ("Khiron" or, the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), is pleased to announce that it has closed today its previously announced underwritten overnight public offering of units of the Company ("Units"), including the exercise in full of the over- allotment option (the... Read more


Cantourage and Clever Leaves intensify strategic partnership for distribution of medical cannabis in Germany

Cantourage introduces second Clever Leaves medical cannabis product to the German market IQANNA No 10, a high-THC dried flower product based on the Wappa cultivar, produced at Clever Leaves' Portugal facility, is available in German pharmacies Caroline Kliess, Managing Director of Clever Leaves Germany, comments: "We are excited to intensify our partnership with Cantourage and launch our next medical cannabis... Read more


Tilray Medical Launches Sleep-Oriented CBN Night Oil for Medical Cannabis Patients in Canada

Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis brand, Aphria, has launched CBN Night Oil, the brand’s first CBN oil medical product formulated for patients’ nighttime use. Blair MacNeil, President,... Read more


Columbia Care Operationalizes Second Cultivation Facility in New Jersey and Expands Adult Use Hours at Both Garden State Cannabist Locations

Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced cultivators, manufacturers and providers of cannabis products in the U.S., announced today it has started operations in its new, approximately 270,000-square-foot cultivation and production facility in New Jersey, begun using post-harvest automation equipment, and... Read more


Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups

New collaborations focused on building library of novel cannabinoid derivatives and small molecules capable of modulating endocannabinoid system Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs, has signed new research agreements with the... Read more


PharmaCielo Announces Shipment of CBD Full Spectrum Oil to a Brazilian Pharmaceutical Customer

The Company has shipped pre-commercial quantities of CBD full spectrum oil containing THC, to support the development of a full spectrum product for the Brazilian market. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S.... Read more


VIVO Cannabis Announces Publication of Medical Cannabis Clinical Research Study in Psychiatric Research: Anxiety & Depression Outcomes in Medical Cannabis...

VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) ("VIVO" or the "Company"), a leading provider of medical cannabis products and patient services, and holder of licenses under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited ("Canna Farms"), ABcann Medicinals Inc., today announced results from its first study investigating how medical cannabis impacts anxiety and depression outcomes. The... Read more


Trulieve Cannabis Celebrates Grand Opening of Medical Dispensary in Coatesville, PA

Trulieve-branded location opens on June 2nd Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the grand opening of a new Trulieve-branded medical marijuana dispensary under the Permit Harvest of SouthEast PA, LLC. in Coatesville, Penn. Located at 1951 E Lincoln Hwy, Coatesville, PA... Read more


Lexaria Bioscience Grants License to Valcon Medical for the European Market

Contract Manufacturing Organization first in Europe to License DehydraTECH Lexaria will receive milestone fees and royalty payments from product sales Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the awarding of a European and United Kingdom ("UK") DehydraTECH license for medical cannabis applications... Read more


Khiron Life Sciences Announces Pricing And Size Of Overnight Brokered Offering

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce that it has priced and sized its previously announced underwritten overnight marketed public offering (the "Offering"). Pursuant to the Offering, the Company will issue 26,700,000 units of the Company (each, a "Unit") at a price of C$0.15 per Unit (the "Offering Price") for aggregate gross proceeds of... Read more


SciSparc Announces Closing of $10 Million Private Placement Priced At-the-Market

SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today closed its previously announced private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately $10 million, before... Read more


Khiron Life Sciences Reports First Quarter 2022 Financial Results with Record Revenue in Medical Cannabis

The Corporation recorded revenues of $4.6 million in Q1 2022, a 65% increase from Q1 2021, and a 28% increase from Q4 2021 Record revenue in medical cannabis of over $2.6 million in Q1 2022, a 470% increase from the prior year and 32% increase from Q4 2021 Gross profit before fair value adjustments grew to $2.1 million, up 96% from Q1 2021, driven primarily by its 75% gross margin medical cannabis business,... Read more


Khiron Life Sciences to Acquire EU-GMP-Certified German Pharmaceuticals Manufacturer and Wholesaler, Expanding its European Footprint

The acquisition will accelerate Khiron's growth in Europe by controlling the complete value chain for its products and gaining direct access to German pharmacies The acquisition will provide Khiron with an EU GMP-certified European manufacturing and distribution hub for various pharmaceutical products The target is an experienced player in the European pharmaceutical market, and the acquisition will help to... Read more


Entourage Health Reports Record First Quarter 2022 Financial Results

Gross revenue* of $17.4 million, up 28% sequentially and 37% year over year Total revenue of $15.8 million in Q1, 2022 represents a 17% sequential increase over Q4 2021 Gross Profit Before Fair Value Changes improved $5.5 million sequentially Adjusted EBITDA improved $1.0 million from Q4 2021, reflecting higher gross profit as Company realizes benefits from strategic transformation initiatives Upsized... Read more


Innocan Pharma Announces Q1 2022 Results with 215% Increase in Cash Balance and 200% Increase in Working Capital

 Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to report its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Operating Highlights: Cash balance at end of Q1-22 - USD 9.5M, in Q1-21 - USD 4.4M, an increase of approximately of 215% from corresponding quarter. Net loss for Q1-22 - USD 0.7M. Net loss in Q1-21 -... Read more


PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2022

The Company expects Revenue to continue to grow – recently shipped 300 kg of CBD Full Spectrum Oil to a Spanish pharmaceutical company, announced entrance into Polish market, and shipments to Germany expected by late 2022. Steadily building pipeline in other key markets. Continued progress on streamlining the business, while continuing to invest in revenue-generating sales functions – SG&A expenses... Read more


SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market

SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $10 million, before deducting fees to the... Read more


SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome

Ethics Committee approval received from the two sites that will conduct the SCI-110 trial in Germany and Israel SciSparc Ltd. (NASDAQ: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it received Ethics Committee approvals from Hannover Medical School in Hannover, Germany,... Read more


Medical Marijuana Launches Pharma Subsidiary in Brazil; Expands Access to CBD Products in Pharmacies

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that it has launched its first pharmaceutical subsidiary, HM Pharma, in Brazil. “We have been working hard to connect and build meaningful relationships with medical... Read more


Clinical Studies Support Charlotte's Web CBD Clinic™ Topicals as Safe for Massage and Frequent Use

Studies indicate CBD Clinic™ hemp topicals for massage do not irritate, or penetrate into the bloodstream, after high-frequency, repeated use such as in massage therapy (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web," "CW" or the "Company"), the market leader in full-spectrum hemp extract CBD products, today announced results from a series of clinical research studies on frequent use... Read more


Item 9 Labs Signs Definitive Agreement to Acquire Sessions Cannabis, One of Canada's Largest Cannabis Retail Franchisors

Transformative Acquisition Creates the Largest, Global and Publicly Traded Cannabis Franchise Company Sessions Cannabis Generates Approximately CA$70 Million in Annual Systemwide Sales With 43 Stores Currently Open Item 9 Labs Corp. (OTCQX: INLB) (the "Company") — a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products — announced today that it... Read more


PharmaCielo Enters Spanish Market with Initial Shipment of 300 kg of CBD Full Spectrum Oil to Pharmaceutical Company

The Company has shipped pharmaceutical grade CBD full spectrum oil containing THC to Extractions Solutions SL, to support pre-commercial development of a full spectrum product for the European market. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of... Read more


Aleafia Health Continues Ascent in Adult-Use Cannabis Market Share Rankings

Adult-use cannabis market share increased three positions to 13th in April 2022 vs 16th in December 2021(1) 53% increase in adult-use market share to 2.5% in April 2022 vs December 2021(2), representing the 5th highest growth rate among the top 40 Canadian LPs Spring & Summer launch of 12 OCS and 8 AGLC SKUs builds depth in key flower, pre-roll and vape product format categories and positions the Company... Read more


Medical Marijuana Reports $7.8 Million in Net Revenue in 2022 First Quarter Financial and Operational Results

 Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its financial results for the quarter ending March 31, 2022, and provided an overview of recent operational highlights. First Quarter 2022 Financial and... Read more


Aurora Cannabis Strengthens Leadership Position in Germany with EU-GMP Certification at Preeminent Local Cannabis Production Facility

State-of-the-art facility readying first delivery of medical grade cannabis for German patients Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the company has received EU-GMP certification for its state-of-the-art medical cannabis production facility in Germany. As a leading manufacturer of medical... Read more


Tetra Bio-Pharma Receives EMA Orphan Drug Designation for a Novel Topical Therapeutic Containing CBD

Novel proprietary cannabidiol (CBD) therapeutic has been classified as an orphan medicinal product for the indication of epidermolysis bullosa (EB). Drug is ready for human clinical trials. Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the European Medicines Agency (EMA) has classified... Read more


Rubicon Organics Obtains Key Certification for International Export

Granted IMC-G.A.P. Certification by the Control Union (“CU”) Milestone to export to Israel and EU-GMP facilities in Europe and Australia Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified, premium cannabis, today announced that its’ Delta Facility has received its CUMCS Equivalency... Read more

COPYRIGHT ©2022 GREEN STOCK NEWS